|
|
 |
|
Viewing report
|
|
|
|
Obesity Drug Markets in the US and EU: Analysis of Product Pipelines and the Competitive Environment
Business Insights, July 2008, Pages: 148
Obesity Drug Markets in the US and EU
Executive Summary
The large and growing obesity problem
Current approaches to obesity management
Pharmaceutical options for the treatment of obesity
The obesity drug pipeline
Market forecasts
Chapter 1 The large and growing obesity problem
Summary
A potentially life threatening medical condition
Levels of obesity
Overweight
Obesity
Morbid obesity
Super obesity
Co-morbidities and mortality
Arthritis
Asthma
Cancer
Cardiovascular disease and hypertension
Dementia
Depression
Diabetes
Kidney disease
Rising prevalence of obesity
Trends by sub-population
United States
Europe
Obesity in children and adolescents
Heavy social and economic impact
Cost burden
Social effects
Societal and other effects
Medical overview of obesity
Pathogenesis of obesity
Physiological factors
Genetic factors
Environmental factors
Lifestyle factors
Psychological factors
Societal trends
Obesity as a component of metabolic syndrome
Conclusion
Chapter 2 Current approaches to obesity management
Summary
Background
Diet and exercise programs
Dieting
Types of programs
Patient volumes
Exercise
Types of programs
Patient volumes
OTC weight loss supplements
Types of products
Patient volumes
Pharmaceutical options
Types of medications
Patient volumes
Surgical intervention
Types of procedures
Patient volumes
Comparison of options
Safety
Efficacy
Cost
Insurance reimbursement
Unmet needs
Conclusion
Chapter 3 Pharmaceutical options for treatment of obesity
Summary
Leading prescription medications
Meridia
Xenical
Acomplia
Others
OTC medicines
Alli
Comparison of pharmaceutical options
Safety
Efficacy
Cost
Insurance reimbursement
Conclusion
Chapter 4 The obesity drug pipeline
Summary
Introduction
Pre-clinical testing
Phase I testing
Phase II testing
Phase III testing
Leading obesity drug candidates
Lorcaserin hydrochloride
Lepislim
Taranabant
Contrave
CP-945,598
Qnexa
Discontinued obesity drug candidates
Conclusion
Chapter 5 Market forecasts
Summary
Introduction
Current sales levels
United States
Europe
Five year forecasts
United States
Europe
Conclusion
Index
List of Figures
Figure 1.1: Rates of obesity and overweight in the US, 1980–2006
Figure 1.2: Rates of obesity and overweight in Europe, 1980–2006
Figure 2.3: Comparison of safety, efficacy and cost of obesity management approaches
Figure 3.4: Comparison of safety, efficacy and cost of pharmaceutical options for obesity management
Figure 4.5: Comparison of leading obesity drug candidates, 2008
Figure 5.6: Obesity medication sales in the US and EU, 2006 and 2007
Figure 5.7: Obesity medication sales by region, 2007
Figure 5.8: Obesity medication sales in the US and EU, 2008–2013
Figure 5.9: Total obesity medication sales by region, 2008–2013
List of Tables
Table 1.1: Proportion of cancers related to obesity 24
Table 1.2: Prevalence of adult overweight and obesity by country, 2003 32
Table 2.3: US and EU patient caseloads for leading obesity management approaches, 2007–12 (millions of persons) 52
Table 2.4: Safety risks associated with obesity management approaches 65
Table 2.5: Comparative efficacy of obesity management approaches 66
Table 3.6: Safety risks associated with leading obesity medications 90
Table 3.7: Safety risks associated with leading obesity management approaches 92
Table 3.8: US cost comparison for leading obesity medications, 2008 93
Table 4.9: Pharmaceutical pipeline for obesity medications 101
Table 4.10: Discontinuations of obesity drug programs 126
Table 5.11: US sales of obesity medications, 2006 and 2007 138
Table 5.12: European sales of obesity medications, 2006 and 2007 139
Table 5.13: US sales of obesity medications in $m, 2008–2012 142
Table 5.14: European sales of obesity medications in $m, 2008–2012 143
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Obesity Drug Discoveries: What The Future Holds + Obesity Tracker
Obesity Drug Discoveries: What the Future Holds
Booming Global Obesity Drug Market
Obesity - The $11 billion market that never was
Obesity Drug Pipeline: Developing Therapies for a Complex Disease
Anti-Obesity Drugs - Global Strategic Business Report
Anti-Obesity Drugs - Trends & Opportunities Worldwide
European Markets for Obesity Surgery Devices
Bariatric (Obesity) Surgical Devices - Global Strategic Business Report
Adult Obesity and Diabetes in the United States 2009
Obesity - Behavioral, Medical, and Surgical Management, 2nd Edition (2009 Update)
Obesity Opinion Leader Forum, 2002
|
|
|
|
